Canadian Cancer Trials Group Bulletins

Trial Management Group


Trial activation: ALC.4

The ALC.4 (E1910) study, A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults, is centrally activated in Canada.

Complexity Level: 1

Eligibility:
Adults aged 30-70 years with confirmed new diagnosis of BCR-ABL negative, B-lineage ALL.

Objectives:
Primary: to evaluate the overall survival associated with blinatumomab

Secondary: minimal residual disease assessment; toxicities associated with treatment; outcome of blood/marrow transplant with or without blinatumomab; incidence of anti-blinatumomab antibody formation

For more information please contact Study Coordinator: Kate Whelan kwhelan@ctg.queensu.ca